BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2:e94416. [PMID: 28978799 DOI: 10.1172/jci.insight.94416] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Peña-Rodríguez M, Vega-Magaña N, García-Benavides L, Zepeda-Nuño JS, Gutierrez-Silerio GY, González-Hernández LA, Andrade-Villanueva JF, Del Toro-Arreola S, Pereira-Suárez AL, Bueno-Topete MR. Butyrate administration strengthens the intestinal epithelium and improves intestinal dysbiosis in a cholestasis fibrosis model. J Appl Microbiol 2021. [PMID: 33982373 DOI: 10.1111/jam.15135] [Reference Citation Analysis]
2 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
3 Zhao F, Dong T, Yuan KY, Wang NJ, Xia FZ, Liu D, Wang ZM, Ma R, Lu YL, Huang ZW. Shifts in the Bacterial Community of Supragingival Plaque Associated With Metabolic-Associated Fatty Liver Disease. Front Cell Infect Microbiol 2020;10:581888. [PMID: 33384967 DOI: 10.3389/fcimb.2020.581888] [Reference Citation Analysis]
4 Chen Y, Liu P, Liu R, Hu S, He Z, Dong G, Feng C, An S, Ying X. Comprehensive Strain-Level Analysis of the Gut Microbe Faecalibacterium prausnitzii in Patients with Liver Cirrhosis. mSystems 2021;6:e0077521. [PMID: 34342541 DOI: 10.1128/mSystems.00775-21] [Reference Citation Analysis]
5 Yu X, Jin Y, Zhou W, Xiao T, Wu Z, Su J, Gao H, Shen P, Zheng B, Luo Q, Li L, Xiao Y. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol 2022;11:761192. [DOI: 10.3389/fcimb.2021.761192] [Reference Citation Analysis]
6 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
7 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
8 Araujo DS, Klein MI, Scudine KGO, de Sales Leite L, Parisotto TM, Ferreira CM, Fonseca FLA, Perez MM, Castelo PM. Salivary Microbiological and Gingival Health Status Evaluation of Adolescents With Overweight and Obesity: A Cluster Analysis. Front Pediatr 2020;8:429. [PMID: 32850543 DOI: 10.3389/fped.2020.00429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett 2020;474:15-22. [PMID: 31917160 DOI: 10.1016/j.canlet.2020.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
10 Mohammed H, Varoni EM, Cochis A, Cordaro M, Gallenzi P, Patini R, Staderini E, Lajolo C, Rimondini L, Rocchetti V. Oral Dysbiosis in Pancreatic Cancer and Liver Cirrhosis: A Review of the Literature. Biomedicines 2018;6:E115. [PMID: 30544974 DOI: 10.3390/biomedicines6040115] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 7.8] [Reference Citation Analysis]
11 Imai J, Kitamoto S, Kamada N. The pathogenic oral-gut-liver axis: new understandings and clinical implications. Expert Rev Clin Immunol 2021;17:727-36. [PMID: 34057877 DOI: 10.1080/1744666X.2021.1935877] [Reference Citation Analysis]
12 Zhou J, Chen S, Ren J, Zou H, Liu Y, Chen Y, Qiu Y, Zhuang W, Tao J, Yang J. Association of enhanced circulating trimethylamine N-oxide with vascular endothelial dysfunction in periodontitis patients. J Periodontol 2021. [PMID: 34472093 DOI: 10.1002/JPER.21-0159] [Reference Citation Analysis]
13 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
14 Gleeson MW. Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia. Curr Treat Options Gastro 2019;17:378-93. [DOI: 10.1007/s11938-019-00241-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Acharya C, Bajaj JS. Is it time to spit? More evidence for the oral-gut-liver axis in liver disease. Hepatol Int 2021;15:4-5. [PMID: 33479868 DOI: 10.1007/s12072-021-10136-3] [Reference Citation Analysis]
16 Suárez LJ, Arboleda S, Angelov N, Arce RM. Oral Versus Gastrointestinal Mucosal Immune Niches in Homeostasis and Allostasis. Front Immunol 2021;12:705206. [PMID: 34290715 DOI: 10.3389/fimmu.2021.705206] [Reference Citation Analysis]
17 Xin Z, Zhai Z, Long H, Zhang F, Ni X, Deng J, Yi L, Deng B. Metabolic Profiling by UPLC-Orbitrap-MS/MS of Liver from C57BL/6 Mice with DSS-Induced Inflammatory Bowel Disease. Mediators Inflamm 2020;2020:6020247. [PMID: 33029104 DOI: 10.1155/2020/6020247] [Reference Citation Analysis]
18 Beyaz Coşkun A, Sağdiçoğlu Celep AG. Therapeutic modulation methods of gut microbiota and gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 33749411 DOI: 10.1080/10408398.2021.1902263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hajishengallis G. Interconnection of periodontal disease and comorbidities: Evidence, mechanisms, and implications. Periodontol 2000 2022. [PMID: 35244969 DOI: 10.1111/prd.12430] [Reference Citation Analysis]
20 Bajaj JS, Matin P, White MB, Fagan A, Deeb JG, Acharya C, Dalmet SS, Sikaroodi M, Gillevet PM, Sahingur SE. Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2018;315:G824-37. [PMID: 30118351 DOI: 10.1152/ajpgi.00230.2018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
21 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
23 Lai S, Iwakiri Y. Is miR-21 a potent target for liver fibrosis? Hepatology 2018;67:2082-4. [PMID: 29315674 DOI: 10.1002/hep.29774] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
24 Helenius-Hietala J, Suominen AL, Ruokonen H, Knuuttila M, Puukka P, Jula A, Meurman JH, Åberg F. Periodontitis is associated with incident chronic liver disease-A population-based cohort study. Liver Int 2019;39:583-91. [PMID: 30300961 DOI: 10.1111/liv.13985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
25 Altay O, Nielsen J, Uhlen M, Boren J, Mardinoglu A. Systems biology perspective for studying the gut microbiota in human physiology and liver diseases. EBioMedicine 2019;49:364-73. [PMID: 31636011 DOI: 10.1016/j.ebiom.2019.09.057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, De Timary P, Leclercq I, Fouts D, Schnabl B, Stärkel P. Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes 2020;12:1782157. [PMID: 32588725 DOI: 10.1080/19490976.2020.1782157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
27 Atif M, Warner S, Oo YH. Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells. Hepatol Int 2018;12:305-14. [PMID: 30027532 DOI: 10.1007/s12072-018-9882-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
28 Herrero R, Sánchez G, Asensio I, López E, Ferruelo A, Vaquero J, Moreno L, de Lorenzo A, Bañares R, Lorente JA. Liver-lung interactions in acute respiratory distress syndrome. Intensive Care Med Exp 2020;8:48. [PMID: 33336286 DOI: 10.1186/s40635-020-00337-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Khor B, Snow M, Herrman E, Ray N, Mansukhani K, Patel KA, Said-Al-Naief N, Maier T, Machida CA. Interconnections Between the Oral and Gut Microbiomes: Reversal of Microbial Dysbiosis and the Balance Between Systemic Health and Disease. Microorganisms 2021;9:496. [PMID: 33652903 DOI: 10.3390/microorganisms9030496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Cui B, Lin L, Wang B, Liu W, Sun C. Therapeutic potential of Saccharomyces boulardii in liver diseases: from passive bystander to protective performer? Pharmacol Res 2021;175:106022. [PMID: 34883213 DOI: 10.1016/j.phrs.2021.106022] [Reference Citation Analysis]
31 Siddiqui MT, Cresci GAM. Microbiota reprogramming for treatment of alcohol-related liver disease. Transl Res 2020;226:26-38. [PMID: 32687975 DOI: 10.1016/j.trsl.2020.07.004] [Reference Citation Analysis]
32 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci. 2020;21:5097. [PMID: 32707678 DOI: 10.1038/s41575-019-0226-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
33 Chen B, Rao X, Wang X, Luo Z, Wang J, Sheng S, Liu Y, Zhang N, Jin S, Chen H, Sun C, Xu T, Du Y. cGAS-STING Signaling Pathway and Liver Disease: From Basic Research to Clinical Practice. Front Pharmacol 2021;12:719644. [PMID: 34483930 DOI: 10.3389/fphar.2021.719644] [Reference Citation Analysis]
34 Baghbani T, Nikzad H, Azadbakht J, Izadpanah F, Haddad Kashani H. Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19. Microb Cell Fact. 2020;19:217. [PMID: 33243230 DOI: 10.1186/s12934-020-01483-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
35 Sung CM, Lin YF, Chen KF, Ke HM, Huang HY, Gong YN, Tsai WS, You JF, Lu MJ, Cheng HT, Lin CY, Kuo CJ, Tsai IJ, Hsieh SY. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell Mol Gastroenterol Hepatol. 2019;8:301-318.e2. [PMID: 31004827 DOI: 10.1016/j.jcmgh.2019.04.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
36 Cӑtoi AF, Corina A, Katsiki N, Vodnar DC, Andreicuț AD, Stoian AP, Rizzo M, Pérez-martínez P. Gut microbiota and aging-A focus on centenarians. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2020;1866:165765. [DOI: 10.1016/j.bbadis.2020.165765] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
37 Chen B, Lin W, Li Y, Bi C, Du L, Liu Y, Zhou L, Liu T, Xu S, Shi C, Zhu H, Wang Y, Sun J, Liu Y, Zhang W, Lu H, Wang Y, Feng Q, Chen F, Wang C, Tonetti MS, Zhu Y, Zhang H, Duan S. Roles of oral microbiota and oral-gut microbial transmission in hypertension. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.03.007] [Reference Citation Analysis]
38 Cornide-Petronio ME, Álvarez-Mercado AI, Jiménez-Castro MB, Peralta C. Current Knowledge about the Effect of Nutritional Status, Supplemented Nutrition Diet, and Gut Microbiota on Hepatic Ischemia-Reperfusion and Regeneration in Liver Surgery. Nutrients 2020;12:E284. [PMID: 31973190 DOI: 10.3390/nu12020284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
39 Yu L, Wang L, Wu X, Yi H. RSPO4-CRISPR alleviates liver injury and restores gut microbiota in a rat model of liver fibrosis. Commun Biol 2021;4:230. [PMID: 33603089 DOI: 10.1038/s42003-021-01747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhang Y, Li JX, Zhang Y, Wang YL. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis . World J Clin Cases 2021; 9(23): 6654-6662 [PMID: 34447812 DOI: 10.12998/wjcc.v9.i23.6654] [Reference Citation Analysis]
41 Hajishengallis G, Li X, Divaris K, Chavakis T. Maladaptive trained immunity and clonal hematopoiesis as potential mechanistic links between periodontitis and inflammatory comorbidities. Periodontol 2000 2022. [PMID: 35244943 DOI: 10.1111/prd.12421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zhong S, Kuang Q, Zhang F, Chen B, Zhong Z. Functional roles of the microbiota-gut-brain axis in Alzheimer’s disease: Implications of gut microbiota-targeted therapy. Translational Neuroscience 2021;12:581-600. [DOI: 10.1515/tnsci-2020-0206] [Reference Citation Analysis]
43 Jin S, Wetzel D, Schirmer M. Deciphering mechanisms and implications of bacterial translocation in human health and disease. Curr Opin Microbiol 2022;67:102147. [PMID: 35461008 DOI: 10.1016/j.mib.2022.102147] [Reference Citation Analysis]
44 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
45 Xiao X, Cheng Y, Fu J, Lu Z, Wang F, Jin M, Zong X, Wang Y. Gut Immunity and Microbiota Dysbiosis Are Associated with Altered Bile Acid Metabolism in LPS-Challenged Piglets. Oxid Med Cell Longev 2021;2021:6634821. [PMID: 33833852 DOI: 10.1155/2021/6634821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Shrestha N, Sleep SL, Cuffe JSM, Holland OJ, McAinch AJ, Dekker Nitert M, Hryciw DH. Pregnancy and diet-related changes in the maternal gut microbiota following exposure to an elevated linoleic acid diet. Am J Physiol Endocrinol Metab 2020;318:E276-85. [PMID: 31846371 DOI: 10.1152/ajpendo.00265.2019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
47 Bajaj JS, Torre A, Rojas ML, Fagan A, Nandez IE, Gavis EA, De Leon Osorio O, White MB, Fuchs M, Sikaroodi M, Gillevet PM. Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico. Liver Int 2020;40:1395-407. [PMID: 32181561 DOI: 10.1111/liv.14437] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Konturek PC, Harsch IA, Konturek K, Schink M, Zopf Y. [Gut-liver axis: How intestinal bacteria affect the liver]. MMW Fortschr Med 2018;160:11-5. [PMID: 30367438 DOI: 10.1007/s15006-018-1051-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
49 Droździk M, Oswald S, Droździk A. Extrahepatic Drug Transporters in Liver Failure: Focus on Kidney and Gastrointestinal Tract. Int J Mol Sci 2020;21:E5737. [PMID: 32785140 DOI: 10.3390/ijms21165737] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Bashiardes S, Abdeen SK, Elinav E. Personalized Nutrition: Are We There Yet? J Pediatr Gastroenterol Nutr 2019;69:633-8. [PMID: 31765333 DOI: 10.1097/MPG.0000000000002491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
51 Li F, McClain CJ, Feng W. Microbiome dysbiosis and alcoholic liver disease. Liver Res 2019;3:218-26. [PMID: 33868760 DOI: 10.1016/j.livres.2019.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
52 Liu Y, Fan L, Cheng Z, Yu L, Cong S, Hu Y, Zhu L, Zhang B, Cheng Y, Zhao P, Zhao X, Cheng M. Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance. Sci Rep 2021;11:1611. [PMID: 33452411 DOI: 10.1038/s41598-021-81263-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
53 Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Åberg F, Helenius-hietala J. Oral Health and Liver Disease: Bidirectional Associations—A Narrative Review. Dentistry Journal 2022;10:16. [DOI: 10.3390/dj10020016] [Reference Citation Analysis]
56 Arsenijevic A, Stojanovic B, Milovanovic J, Arsenijevic D, Arsenijevic N, Milovanovic M. Galectin-3 in Inflammasome Activation and Primary Biliary Cholangitis Development. Int J Mol Sci 2020;21:E5097. [PMID: 32707678 DOI: 10.3390/ijms21145097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
57 Dong M, Xu X, Huang Q, Lei H, Xu G, Ma J, Hatzakis E, Wang X, Zhang L. Dose-Dependent Effects of Triclocarban Exposure on Lipid Homeostasis in Rats. Chem Res Toxicol 2019;32:2320-8. [DOI: 10.1021/acs.chemrestox.9b00316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
58 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
60 Oikonomou T, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. World J Gastroenterol 2018; 24(34): 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
61 Vaughn BP, Rank KM, Khoruts A. Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease. Clin Gastroenterol Hepatol. 2019;17:353-361. [PMID: 30055267 DOI: 10.1016/j.cgh.2018.07.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
62 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
63 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Mester A, Ciobanu L, Taulescu M, Apostu D, Lucaciu O, Filip GA, Feldrihan V, Licarete E, Ilea A, Piciu A, Oltean‐dan D, Scurtu I, Berce C, Campian RS. Periodontal disease may induce liver fibrosis in an experimental study on Wistar rats. J Periodontol 2019;90:911-9. [DOI: 10.1002/jper.18-0585] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
65 Philips CA, Augustine P. Gut Barrier and Microbiota in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.08.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Reddy YK, Maliakkal B, Agbim U. Nutrition in Chronic Liver Disease. Curr Treat Options Gastro 2019;17:602-18. [DOI: 10.1007/s11938-019-00252-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
67 Mohieldeen K, Hamoda SAF, Ahmed SM, Najeeb A, Ellakany WI. Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00147-y] [Reference Citation Analysis]
68 Li Y, Cui J, Liu Y, Chen K, Huang L, Liu Y. Oral, Tongue-Coating Microbiota, and Metabolic Disorders: A Novel Area of Interactive Research. Front Cardiovasc Med 2021;8:730203. [PMID: 34490384 DOI: 10.3389/fcvm.2021.730203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatol Res 2019;49:232-8. [PMID: 30198141 DOI: 10.1111/hepr.13249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
72 Eom JA, Kwon GH, Kim NY, Park EJ, Won SM, Jeong JJ, Raja G, Gupta H, Asmelash Gebru Y, Sharma S, Choi YR, Kim HS, Yoon SJ, Hyun JY, Jeong MK, Park HJ, Min BH, Choi MR, Kim DJ, Suk KT. Diet-Regulating Microbiota and Host Immune System in Liver Disease. Int J Mol Sci 2021;22:6326. [PMID: 34199182 DOI: 10.3390/ijms22126326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Peng W, Li H, Zhao X, Shao B, Zhu K. Pyocyanin Modulates Gastrointestinal Transformation and Microbiota. J Agric Food Chem 2022. [PMID: 35171599 DOI: 10.1021/acs.jafc.1c07726] [Reference Citation Analysis]
74 Sakanaka A, Kuboniwa M, Katakami N, Furuno M, Nishizawa H, Omori K, Taya N, Ishikawa A, Mayumi S, Tanaka Isomura E, Shimomura I, Fukusaki E, Amano A. Saliva and Plasma Reflect Metabolism Altered by Diabetes and Periodontitis. Front Mol Biosci 2021;8:742002. [PMID: 34589520 DOI: 10.3389/fmolb.2021.742002] [Reference Citation Analysis]
75 Liu Y, Huang W, Wang J, Ma J, Zhang M, Lu X, Liu J, Kou Y. Multifaceted Impacts of Periodontal Pathogens in Disorders of the Intestinal Barrier. Front Immunol 2021;12:693479. [PMID: 34386004 DOI: 10.3389/fimmu.2021.693479] [Reference Citation Analysis]
76 Enguita M, Razquin N, Pamplona R, Quiroga J, Prieto J, Fortes P. The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells. Cell Death Dis 2019;10:14. [PMID: 30622239 DOI: 10.1038/s41419-018-1243-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
77 Ezzeldin S, El-Wazir A, Enany S, Muhammad A, Johar D, Osama A, Ahmed E, Shikshaky H, Magdeldin S. Current Understanding of Human Metaproteome Association and Modulation. J Proteome Res 2019;18:3539-54. [PMID: 31262181 DOI: 10.1021/acs.jproteome.9b00301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]